Subcutaneous NSCLC Treatments Offer Faster Management, reduced Side Effects, Expert Says
NEW YORK – Subcutaneous formulations of cancer therapies are poised to considerably improve care for patients with non-small cell lung cancer (NSCLC), offering decreased chair time, easier administration, and potentially lower healthcare costs, according to Joshua K. Sabari, MD.The shift towards subcutaneous delivery is already underway with PD-1 and PD-L1 inhibitors like nivolumab, atezolizumab, and pembrolizumab, and is expanding to target other NSCLC subtypes.
Currently, amivantamab, an EGFR and MET bispecific antibody used in patients with EGFR mutation-positive NSCLC, is administered intravenously.However, a subcutaneous formulation is in advancement that promises to dramatically reduce treatment time and infusion-related reactions. “We are developing a subcutaneous formulation which dramatically decreases the rate of the infusion or injection time, decreasing chair time, leading to patient enhancement and satisfaction,” Dr. Sabari explained.
Clinical data suggests a meaningful reduction in infusion-related reactions with the subcutaneous formulation-affecting approximately 10% of patients compared to roughly two-thirds with the IV version.
Beyond convenience, Dr. Sabari envisions a future where subcutaneous therapies could be administered in settings outside traditional cancer centers, such as patients’ homes or nursing facilities, with appropriate medical oversight. “Think about the future where these therapies may be able to be given in the home or in nursing centers, obviously, with appropriate oversight and appropriate care,” he saeid.
EGFR mutations are present in 25% to 30% of all lung cancers, making this a notably impactful area for innovation. Dr. Sabari emphasized the importance of prioritizing patient needs while implementing these advancements. “I think we need to do it in a smart fashion. We need to do this with supervision, but also really need to keep patients in the center of the discussion and continue to do what’s best for patient care.”
